Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials

Numerous biologics are currently licensed for the treatment of psoriasis, including new drugs targeting interleukin-17 (IL-17) and interleukin-23 (IL-23). This meta-analysis evaluated the short-term (12–16 weeks) efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International immunopharmacology 2018-09, Vol.62, p.46-58
Hauptverfasser:	Cui, Lian, Chen, Rongfen, Subedi, Smriti, Yu, Qian, Gong, Yu, Chen, Zeyu, Shi, Yuling
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Biological effects Biological products Biologics Clinical trials Drug delivery Effectiveness Humans IL-17 IL-23 Immunologic Factors - administration & dosage Immunologic Factors - adverse effects Immunologic Factors - therapeutic use Interleukin 17 Interleukin 23 Interleukin-17 - antagonists & inhibitors Interleukin-17 - immunology Interleukin-23 - antagonists & inhibitors Interleukin-23 - immunology Medical research Meta-analysis Monoclonal antibodies Plaque Psoriasis Psoriasis - drug therapy Psoriasis - immunology Randomization Randomized Controlled Trials as Topic Risk Safety Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Numerous biologics are currently licensed for the treatment of psoriasis, including new drugs targeting interleukin-17 (IL-17) and interleukin-23 (IL-23). This meta-analysis evaluated the short-term (12–16 weeks) efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis. Twenty-one randomized clinical trials met the defined inclusion criteria. Our results showed that Ixekizumab (160 mg wk0 + 80 mg q2w) had the greatest probability of achieving both PASI 75 (RR 21.32, 95% CI 15.48–29.36, P
ISSN:	1567-5769 1878-1705
DOI:	10.1016/j.intimp.2018.06.020